Categories AlphaGraphs, Earnings, Technology

Infographic: DocuSign (DOCU) 4Q revenue up 14%: to realign sales force

DocuSign, Inc. (NASDAQ: DOCU), a leading provider of electronic signature solutions, has reported fourth-quarter 2023 earnings. It also provided guidance for the first quarter and fiscal 2024.

The top line increased by 14% to $659.6 million. Consequently, adjusted earnings advanced 35% annually to $0.65 per share. Fourth-quarter net profit was $0.02 per share or $4.9 million, compared to a loss of $30.4 million or $0.15 per share in the year-ago fiscal quarter. Net income mainly reflects interest income and income from other sources.

DocuSign Q4 2023 earnings infographic

The subscription segment accounted for about 98% of total revenues, while the remaining came from the professional services division. Billings increased 10% year-over-year to $739 million. Cash, cash equivalents, restricted cash, and investments were $1.2 billion at the end of the quarter.

In fiscal 2023, the net loss widened to $97.5 million due to a 20% increase in operating expenses, and the management expects the trend to persist in the coming quarters.

Outlook

For the first quarter of 2024, total revenue is expected to be in the range of $639 million to $643 million. Subscription revenue is forecast to be between $625 million and $629 million, while billings are expected to be in the $615-$625-million range. For fiscal 2024, revenue is expected to be between $2.695 billion and $2.707 billion, and billings in the range of $2.705 billion to $2.725 billion.

Prior Performance

  • DocuSign Q3 2023 earnings infographic
  • DocuSign-Q2-2023-Earnings-Infographic
  • DocuSign Q1 2023 earnings infographic
  • DocuSign Q4 2022 earnings infographic

_________________________________________________________________________________________________________________

Stocks you may like:

Apple (AAPL) Stock

Microsoft (MSFT) Stock

Alphabet (GOOGL) Stock

International Business Machines Corp. (IBM) Stock

_________________________________________________________________________________________________________________

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top